An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients

NCT07142057 | Not Yet Recruiting DMC

• 1 other identifier: 23V-PNEUMO-LC
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.

Conditions

LUNG CANCER

Outcome Measures

Primary Outcomes (2)

• The incidence of pneumonia at 12 months

  During the 12-month follow-up period, the incidence of pulmonary infection in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.

  12 months

• Incidence of pneumonia

  The proportion of lung cancer patients who developed pneumonia during the study period.

  24 months

Secondary Outcomes (1)

• Survival rate

  5 years

Other Outcomes (7)

• Lung cancer-related complications

  5 years

• Length of hospital stay

  5 years

• Hospitalization rate

  5 years

Study Arms (2)

Vaccination group

Lung cancer patients receive 23-valent pneumonia vaccine

Biological: 23-valent pneumococcal vaccine

Unvaccinated group

Lung cancer patients have not received the 23-valent pneumococcal vaccine

Interventions

23-valent pneumococcal vaccine BIOLOGICAL

Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine

Vaccination group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Lung cancer patients can receive or not receive the 23-valent pneumococcal vaccine

You may qualify if:

• Male or female patients \>=18 years of age;
• Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;
• Never received pneumococcal vaccine

You may not qualify if:

• Patients having other factors that preventing researchers from enrollment them.

Sponsors & Collaborators

• The First Affiliated Hospital of Guangzhou Medical University: lead

MeSH Terms

Conditions

Lung Neoplasms

Interventions

23-valent pneumococcal capsular polysaccharide vaccine

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: The First Affiliated Hospital of Guangzhou Medical University

Study Record Dates

• First Submitted: August 19, 2025
• First Posted: August 26, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2030
• Last Updated: August 26, 2025

Record last verified: 2025-08